JNJ vs. MS

Last updated Jun 9, 2026

JNJ (Johnson & Johnson) and MS (Morgan Stanley) are both stocks. JNJ operates in Drug Manufacturers - General (Healthcare), while MS operates in Capital Markets (Financial Services). Over the past 10 years, JNJ returned 10.06%/yr vs 27.13%/yr for MS. At a 0.27 correlation, their price movements are largely independent.

Performance

JNJ vs. MS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Johnson & Johnson (JNJ) and Morgan Stanley (MS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, JNJ achieves a 13.43% return, which is significantly lower than MS's 20.86% return. Over the past 10 years, JNJ has underperformed MS with an annualized return of 10.06%, while MS has yielded a comparatively higher 27.13% annualized return.

JNJ

• 1D: -0.26%
• 1M: 5.50%
• YTD: 13.43%
• 6M: 16.43%
• 1Y: 53.49%
• 3Y*: 16.56%
• 5Y*: 10.04%
• 10Y*: 10.06%

MS

• 1D: 0.15%
• 1M: 9.92%
• YTD: 20.86%
• 6M: 21.34%
• 1Y: 64.89%
• 3Y*: 39.40%
• 5Y*: 21.89%
• 10Y*: 27.13%

*Multi-year figures are annualized to reflect compound growth (CAGR)

JNJ vs. MS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
JNJ Johnson & Johnson	13.43%	47.48%	-4.81%	-8.58%	5.97%	11.44%	10.82%	16.22%	-5.13%	24.43%
MS Morgan Stanley	20.86%	45.16%	39.73%	13.93%	-10.34%	46.65%	38.09%	32.67%	-22.76%	26.61%

Correlation

The correlation between JNJ and MS is -0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.08
Correlation (5Y) Calculated over the trailing 5-year period	0.14
Correlation (10Y) Calculated over the trailing 10-year period	0.20
Correlation (All Time) Calculated using the full available price history since Feb 24, 1993	0.27

The correlation between JNJ and MS shifts across timeframes, from -0.07 (1 year) to 0.27 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap JNJ : $567.68B MS : $338.10B
EPS JNJ : $8.65 MS : $11.41
PE Ratio JNJ : 26.85 MS : 18.59
PEG Ratio JNJ : 0.89 MS : 1.75
PS Ratio JNJ : 5.86 MS : 2.81
PB Ratio JNJ : 6.99 MS : 3.23
Total Revenue (TTM) JNJ : $96.36B MS : $120.22B
Gross Profit (TTM) JNJ : $66.60B MS : $69.72B
EBITDA (TTM) JNJ : $31.62B MS : $27.21B

Return for Risk

JNJ vs. MS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JNJ

JNJ Risk / Return Rank: 95
JNJ Sharpe Ratio Rank: 96
JNJ Sortino Ratio Rank: 97
JNJ Omega Ratio Rank: 95
JNJ Calmar Ratio Rank: 92
JNJ Martin Ratio Rank: 93

MS

MS Risk / Return Rank: 90
MS Sharpe Ratio Rank: 93
MS Sortino Ratio Rank: 90
MS Omega Ratio Rank: 91
MS Calmar Ratio Rank: 86
MS Martin Ratio Rank: 90

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JNJ vs. MS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Johnson & Johnson (JNJ) and Morgan Stanley (MS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	JNJ	MS	Difference
Sharpe ratio: Return per unit of total volatility	3.19	2.55	+0.64
Sortino ratio: Return per unit of downside risk	4.65	3.16	+1.49
Omega ratio: Gain probability vs. loss probability	1.57	1.43	+0.14
Calmar ratio: Return relative to maximum drawdown	4.91	3.46	+1.44
Martin ratio: Return relative to average drawdown	14.52	11.46	+3.06
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

JNJ vs. MS - Sharpe Ratio Comparison

The current JNJ Sharpe Ratio is 3.19, which is comparable to the MS Sharpe Ratio of 2.55. The chart below compares the historical Sharpe Ratios of JNJ and MS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	JNJ	MS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.19	2.55	+0.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.60	0.77	-0.17
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.55	0.86	-0.32
Sharpe Ratio (All Time) Calculated using the full available price history	0.54	0.29	+0.24

Drawdowns

JNJ vs. MS - Drawdown Comparison

The maximum JNJ drawdown since its inception was -50.67%, smaller than the maximum MS drawdown of -88.12%. Use the drawdown chart below to compare losses from any high point for JNJ and MS.

Drawdown Indicators

	JNJ	MS	Difference
Max Drawdown Largest peak-to-trough decline	-50.67%	-88.12%	+37.45%
Max Drawdown (1Y) Largest decline over 1 year	-10.96%	-18.83%	+7.87%
Max Drawdown (3Y) Largest decline over 3 years	-15.95%	-29.24%	+13.29%
Max Drawdown (5Y) Largest decline over 5 years	-18.41%	-32.38%	+13.97%
Max Drawdown (10Y) Largest decline over 10 years	-27.37%	-51.33%	+23.96%
Current Drawdown Current decline from peak	-6.06%	-2.76%	-3.30%
Average Drawdown Average peak-to-trough decline	-11.88%	-33.70%	+21.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.70%	5.68%	-1.98%

Volatility

JNJ vs. MS - Volatility Comparison

The current volatility for Johnson & Johnson (JNJ) is 5.80%, while Morgan Stanley (MS) has a volatility of 8.06%. This indicates that JNJ experiences smaller price fluctuations and is considered to be less risky than MS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JNJ	MS	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.80%	8.06%	-2.26%
Volatility (6M) Calculated over the trailing 6-month period	12.41%	21.21%	-8.80%
Volatility (1Y) Calculated over the trailing 1-year period	16.87%	25.62%	-8.75%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.87%	28.72%	-11.85%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.47%	31.51%	-13.04%

Dividends

JNJ vs. MS - Dividend Comparison

JNJ's dividend yield for the trailing twelve months is around 2.26%, more than MS's 1.88% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
JNJ Johnson & Johnson	2.26%	2.48%	3.40%	3.00%	2.52%	2.45%	2.53%	2.57%	2.74%	2.38%	2.73%	2.87%
MS Morgan Stanley	1.88%	2.17%	2.82%	3.49%	3.47%	2.14%	2.04%	2.54%	2.77%	1.72%	1.66%	1.73%

Financials

JNJ vs. MS - Profitability Comparison

The chart below illustrates the profitability comparison between Johnson & Johnson and Morgan Stanley over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a gross profit of 17.20B and revenue of 24.06B. Therefore, the gross margin over that period was 71.5%.

MS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Morgan Stanley reported a gross profit of 20.48B and revenue of 33.15B. Therefore, the gross margin over that period was 61.8%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported an operating income of 6.40B and revenue of 24.06B, resulting in an operating margin of 26.6%.

MS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Morgan Stanley reported an operating income of 7.01B and revenue of 33.15B, resulting in an operating margin of 21.2%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a net income of 5.24B and revenue of 24.06B, resulting in a net margin of 21.8%.

MS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Morgan Stanley reported a net income of 5.64B and revenue of 33.15B, resulting in a net margin of 17.0%.

Frequently Asked Questions

Can I hold both JNJ and MS in my portfolio?

JNJ and MS have a correlation of -0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, JNJ or MS?

MS has higher volatility (8.06%) compared to JNJ (5.80%). In terms of maximum drawdown, JNJ dropped -50.67% vs MS's -88.12%.

Which has better risk-adjusted returns?

JNJ currently has the higher Sharpe Ratio (3.19 vs 2.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.